Related Experiment Videos
Interactions of antioestrogens and aromatase inhibitors
1Department of Oncology and Hematology, Charité Campus Mitte, Humboldt University Berlin, Germany.
Abstract:
Aromatase inhibitors and antioestrogens have shown substantial activity in primary and advanced breast cancer. Since they exhibit different modes of action, attempts have been made to combine them or to use them sequentially in order to potentially increase their efficacy. In preclinical studies, combined, sequential or alternating treatments with aromatase inhibitors and antioestrogens have failed to provide higher antitumoural activity. There are relevant pharmacokinetic interactions resulting in decreased plasma concentrations of third generation aromatase inhibitors when combined with tamoxifen. Several randomised clinical trials comparing single agent and combined treatment with tamoxifen and aminoglutethimide failed to show any benefit for the combination. Early results of the adjuvant ATAC trial indicate that single agent anastrozole is superior to tamoxifen or the combination of both. Several trials are ongoing which might help to further define the role of sequential or combined treatment with aromatase inhibitors and antioestrogens. However, to date, looking at the current evidence, combined treatment with aromatase inhibitors and antioestrogens does not appear to provide additional benefit compared to single agent treatment.
Insights
Combining aromatase inhibitors and antioestrogens for breast cancer treatment does not show additional benefit over single-agent therapy. Current evidence suggests no improved efficacy or antitumoural activity with combined or sequential use.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Aromatase inhibitors and antioestrogens are active in breast cancer treatment.
- Different mechanisms of action prompt combination or sequential therapy investigations.
- Preclinical and clinical studies have explored combined and sequential treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of combined or sequential treatments with aromatase inhibitors and antioestrogens in breast cancer.
- To assess potential pharmacokinetic interactions between these drug classes.
- To review current evidence regarding combination therapy versus single-agent treatment.
Main Methods:
- Review of preclinical studies on combined, sequential, and alternating treatments.
- Analysis of randomized clinical trials comparing single-agent and combined tamoxifen and aminoglutethimide.
- Examination of early results from the adjuvant ATAC trial comparing anastrozole and tamoxifen.
- Consideration of ongoing clinical trials.
Main Results:
- Preclinical studies showed no increased antitumoural activity with combined or sequential treatments.
- Pharmacokinetic interactions, like decreased aromatase inhibitor levels with tamoxifen, were observed.
- Randomized trials failed to demonstrate benefit for combined tamoxifen and aminoglutethimide.
- Early ATAC trial results suggest anastrozole monotherapy is superior to tamoxifen or combination therapy.
Conclusions:
- Current evidence indicates that combined treatment with aromatase inhibitors and antioestrogens does not offer additional benefit over single-agent therapy.
- Further trials are ongoing to clarify the role of sequential or combined treatments.
- Single-agent therapy remains the standard, with no proven advantage for combination approaches to date.